ArticleAmerican journal of translational research2026
SKA3 promotes cell growth and metastasis and is associated with poor prognosis in patients with esophageal cancer.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOverexpression of Spindle and Kinetochore Associated complex subunit 3 (SKA3) has been strongly implicated in tumor prognosis, proliferation, and metastasis in various cancers. However, its role in esophageal cancer (ESCA) remained unexplored. This study aims to investigate the function of SKA3 in ESCA.
methodsThe expression and prognostic value of SKA3 in ESCA were analyzed through bioinformatics, followed by experimental validation using clinical tissue samples from our hospital. Functional assays were performed to elucidate the role of SKA3 in promoting ESCA cell proliferation and migration. Additionally, the relationship between SKA3 expression and the tumor immune microenvironment was examined.
resultsSKA3 was significantly overexpressed in ESCA, with its elevated expression strongly correlating with key clinical features such as Barrett's esophagus, deeper tumor infiltration, lymph node metastasis, advanced pathologic stage, and poor prognosis. Genes co-expressed with SKA3 were enriched in processes related to cell division, DNA replication, the cell cycle, and the p53 signaling pathway. Knockdown of SKA3 significantly reduced ESCA cell proliferation and migration. Moreover, SKA3 overexpression was associated with higher stromal, immune, and ESTIMATE scores.
conclusionSKA3 contributes to poor prognosis and modulates the immune microenvironment in ESCA. Inhibition of SKA3 expression effectively suppressed tumor growth and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.